U.S. Stem Cell, Inc. USRM -We caught USRM for some nice gain opportunities a couple of weeks back. We had initially begun tracking this play after mentioning it on the morning of February 27th. Subsequent to that, we had witnessed an impressive run from a low of .014 to .0545, for a 289% gain in a span of just two sessions.
That was followed by an expected period of consolidation, but it appears as if USRM has found support at .0175. We're going to want to return to monitoring this play more closely on the chance that it could be gearing up for another run. If it produced a move even a fraction of what we saw before, it will be worth its slot on our watchscreens.
Iconic Brands, Inc. ICNB – Speaking of familiar plays that could be in line for a rebound in upcoming sessions, we want to swing back around to ICNB this week. We had tracked this one to some decent gains after tagging it for observation on January 24th. Following that, the stock would trade in a range from .018 up to .0339, a respectable move of 88%
But like the above-mentioned stock, after its run, it basically underwent a big-time consolidation which lasted nearly a whole month. That brings us up to yesterday, when we noticed ICNB giving off something of a rebound signal. We'll go back to watching more closely in the next few sessions.
Aralez Pharmaceuticals, Inc. ARLZ – Bottom Watcher
ARLZ has been falling off a cliff this week, and despite the fact that it may yet have further to fall, we're going to want to begin monitoring it as it attempts to sniff out a solid support level. There could definitely be some opportunities waiting for traders that can properly time the recovery.
Apart from some quick chances for early gains yesterday, our freshly formulated options idea for JNUG may need some time to mature. That's why we chose an expiration date a couple of weeks out. We'll continue to have the JNUG 03/31 $7-8 Calls on our radars moving forward.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Our disclaimer is to be read and fully agreed to before using our site, or joining our email list. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions, however any that may occur will be corrected as needed. BHS and its affiliates are not registered or licensed investment advisers, nor broker dealers. BHS cautions that the investments in companies profiled are commonly considered to be extremely high risk and use of any information provided is at the investor's sole risk.